BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Net of Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Net of Tax of -$18.30 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-02-27
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for the quarter ending 2018-12-31 was $7.43M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for the quarter ending 2018-09-30 was -$1.03M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for the quarter ending 2018-06-30 was $27.42M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for the quarter ending 2018-03-31 was -$5.00M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for fiscal 2022 was -$18.30M, a 159.86% decline from fiscal 2021.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for fiscal 2021 was $30.57M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for fiscal 2020 was -$36.30M, a 343.76% decline from fiscal 2019.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), net of tax for fiscal 2019 was $14.89M, a 48.32% decline from fiscal 2018.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$18.30M 10-K · filed 2023-02-27 | |||
| 2021-12-31 | $30.57M 10-K · filed 2023-02-27 | |||
| 2020-12-31 | -$36.30M 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $14.89M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $7.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $6.40M derived: sum of 2 quarters · filed 2021-02-26 | $33.82M derived: sum of 3 quarters · filed 2021-02-26 | $28.82M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $26.39M derived: sum of 2 quarters · filed 2018-10-26 | $21.39M 10-Q · filed 2018-10-26 | $19.86M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $27.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $22.42M 10-Q · filed 2018-08-03 | $20.89M derived: sum of 3 quarters · filed 2020-02-27 | $14.12M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$5.00M 10-Q · filed 2018-04-27 | -$6.53M derived: sum of 2 quarters · filed 2020-02-27 | -$13.30M derived: sum of 3 quarters · filed 2020-02-27 | -$32.98M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$8.30M derived: sum of 2 quarters · filed 2020-02-27 | -$27.98M derived: sum of 3 quarters · filed 2020-02-27 | -$35.78M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$6.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | -$26.45M derived: sum of 2 quarters · filed 2017-10-31 | -$34.25M 10-Q · filed 2017-10-31 | -$23.59M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$19.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$27.47M 10-Q · filed 2017-08-02 | -$16.82M derived: sum of 3 quarters · filed 2019-02-28 | -$19.19M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$7.80M 10-Q · filed 2017-05-04 | $2.86M derived: sum of 2 quarters · filed 2019-02-28 | $492.00K derived: sum of 3 quarters · filed 2019-02-28 | $4.97M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $10.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $8.29M derived: sum of 2 quarters · filed 2019-02-28 | $12.77M derived: sum of 3 quarters · filed 2019-02-28 | -$8.22M 10-K · filed 2019-02-28 |
| 2016-09-30 | -$2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $2.11M derived: sum of 2 quarters · filed 2016-11-03 | -$18.88M 10-Q · filed 2016-11-03 | -$23.03M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $4.48M 10-Q · filed 2016-08-08 | -$16.50M 10-Q · filed 2016-08-08 | -$20.66M derived: sum of 3 quarters · filed 2018-02-26 | -$27.93M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | -$20.99M 10-Q · filed 2016-05-02 | -$25.14M derived: sum of 2 quarters · filed 2018-02-26 | -$32.41M derived: sum of 3 quarters · filed 2018-02-26 | -$43.77M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | -$4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$11.43M derived: sum of 2 quarters · filed 2018-02-26 | -$22.79M derived: sum of 3 quarters · filed 2018-02-26 | -$6.43M 10-K · filed 2018-02-26 |
| 2015-09-30 | -$7.28M 10-Q · filed 2015-11-02 | -$18.64M derived: sum of 2 quarters · filed 2016-08-08 | -$2.28M 10-Q · filed 2015-11-02 | $6.00M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | -$11.36M 10-Q · filed 2016-08-08 | $5.00M 10-Q · filed 2016-08-08 | $13.27M derived: sum of 3 quarters · filed 2017-02-27 | $22.52M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $16.35M 10-Q · filed 2016-05-02 | $24.63M derived: sum of 2 quarters · filed 2017-02-27 | $33.88M derived: sum of 3 quarters · filed 2017-02-27 | $36.54M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $17.52M derived: sum of 2 quarters · filed 2017-02-27 | $20.19M derived: sum of 3 quarters · filed 2017-02-27 | $22.45M 10-K · filed 2017-02-27 |
| 2014-09-30 | $9.25M 10-Q · filed 2015-11-02 | $11.91M derived: sum of 2 quarters · filed 2015-11-02 | $14.17M 10-Q · filed 2015-11-02 | $7.72M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $2.67M 10-Q · filed 2015-08-05 | $4.92M 10-Q · filed 2015-08-05 | -$1.53M derived: sum of 3 quarters · filed 2016-02-29 | $7.50M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $2.26M 10-Q · filed 2015-05-05 | -$4.20M derived: sum of 2 quarters · filed 2016-02-29 | $4.83M derived: sum of 3 quarters · filed 2016-02-29 | $6.12M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$6.46M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.58M derived: sum of 2 quarters · filed 2016-02-29 | $3.86M derived: sum of 3 quarters · filed 2016-02-29 | $5.22M 10-K · filed 2016-02-29 |
| 2013-09-30 | $9.03M 10-Q · filed 2014-10-28 | $10.32M derived: sum of 2 quarters · filed 2014-10-28 | $11.68M 10-Q · filed 2014-10-28 | |
| 2013-06-30 | $1.29M 10-Q · filed 2014-07-31 | $2.64M 10-Q · filed 2014-07-31 | ||
| 2013-03-31 | $1.36M 10-Q · filed 2014-05-02 | |||
| 2012-12-31 | -$5.09M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $4.70M 10-K · filed 2014-02-26 | |||
| 2010-12-31 | -$745.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |